EGFR and lung cancer: Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib (HCC827rERLO2μm, HCC4006rERLO1μm) and afatinib (HCC827rAFA50nm, HCC4006rAFA100nm).